North America Next-generation Sequencing Market
North America Next-generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Service, Application (Drug Discovery, Diagnostic, Agriculture)-Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The North America next-generation sequencing market is projected to reach USD 11.63 billion by 2030 from USD 6.15 billion in 2025, at a CAGR of 13.6% from 2025 to 2030. The expansion of the North American NGS market is driven by increasing adoption of sequencing in oncology and precision medicine, the growing prevalence of cancer and other chronic diseases, and ongoing advances that lower sequencing costs while enhancing throughput and data quality.
KEY TAKEAWAYS
-
By RegionThe US next-generation sequencing (NGS) market accounted for a 93.0% revenue share in 2024.
-
By OfferingsBy offering, the North America next-generation sequencing (NGS) market services segment is expected to register the highest growth rate.
-
Product Market, By TypeIn the product market, by type, the consumables segment is expected to dominate the market.
-
Services Market, By TypeIn the services market, by type, the sequencing market segment is expected to dominate the market.
-
Products Market, By End userIn the product market, by end user, the pharmaceutical & biotechnology companies segment is projected to grow at the fastest rate from 2025 to 2030.
-
Services Market, By End userIn the services market, by end user, the academic & research institutes segment is projected to grow at the fastest rate from 2025 to 2030.
-
By ApplicationBy application, the diagnostics segment is projected to grow at the fastest rate from 2025 to 2030.
-
Competitive LandscapeCompany Illumina, Inc., Thermo Fisher Scientific, and Agilent Technologies were identified as some of the star players in the North American next-generation sequencing (NGS) market, given their strong market share and product footprint.
-
Competitive LandscapeCompanies Creative Biogene, Psomagen, and CD Genomics, among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders
The North America next-generation sequencing (NGS) market is witnessing robust growth, fueled by rising demand for high-throughput genomic technologies that enable precise disease diagnosis, targeted therapy selection, and advanced research applications. Increased utilization of NGS in oncology, rare disease testing, reproductive health, and liquid biopsy, combined with supportive reimbursement policies and strong adoption by academic centers, reference laboratories, and biopharmaceutical companies, is strengthening market momentum.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on stakeholders’ businesses in the North America NGS market comes from shifting healthcare priorities, technological disruptions, and changing patient expectations. Hospitals, reference laboratories, academic and research institutions, and biopharmaceutical companies are the main adopters of NGS solutions, with uses mainly in oncology, rare disease diagnostics, reproductive health, and drug development. Increasing focus on precision medicine, companion diagnostics, and large-scale genomic programs is making high-throughput sequencing a vital part of clinical and research workflows across the region.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Clinical adoption of NGS in precision medicine
-
Strong research ecosystem and public funding for genomics
Level
-
High implementation and operating costs for NGS
Level
-
NGS integrated with AI, multi-omics, and digital health in R&D
-
Population-scale genomics and preventive health programs
Level
-
Regulatory, reimbursement, and standardization hurdles
-
Data management, privacy, and interoperability issues
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Clinical adoption of NGS in precision medicine
In North America, NGS is increasingly integrated into routine care across oncology, rare diseases, reproductive health, and infectious disease testing. Comprehensive genomic profiling and large targeted panels are becoming standard in major cancer centers and commercial reference labs, supported by companion diagnostics and guideline recommendations. This shift is moving test volumes from single-gene assays to multi-gene NGS panels, expanding both the installed instrument base and the demand for recurring consumables. As precision medicine programs deepen, clinical test volumes are expected to remain the main source of growth for the regional NGS market.
Restraint: High implementation and operating costs for NGS
Even as the cost per genome declines, labs are facing substantial capital outlays for sequencers, automation, high-performance computing, and secure data storage. Clinical-grade workflows require validated reagents, quality systems, and often redundant platforms, which add to ongoing operating expenses. Smaller hospitals and regional labs often struggle to achieve the scale necessary to make these investments economically viable. This cost structure limits the diffusion of in-house NGS and sustains dependence on a relatively small number of high-volume reference labs.
Opportunity: NGS integrated with AI, multi-omics, and digital health in R&D
Biopharma and leading academic centers in North America are rapidly combining NGS with AI and ML, single-cell omics, and digital-health tools to accelerate drug discovery and clinical development. AI-driven variant interpretation and biomarker discovery can enhance trial stratification, decrease failure rates, and facilitate adaptive study designs. There is also growing interest in using NGS-based monitoring and real-world evidence to inform label expansions and post-marketing commitments. This convergence creates opportunities for NGS vendors to move up the value chain into analytics, decision support, and partnership-based research and development platforms.
Challenge: Regulatory, reimbursement, and standardization hurdles.
The regulatory environment for NGS-based tests in North America is evolving, with differing pathways for LDTs, IVD kits, and companion diagnostics. The lack of uniform standards for analytical validity, clinical validity, and quality management makes it more challenging to scale tests across multiple sites. Reimbursement is a challenge, as payer policies vary by indication and panel size, creating uncertainty in revenue projections for clinical labs. These factors complicate market access and lengthen time-to-adoption for new NGS-based assays.
North America Next-generation Sequencing Market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
The research team at the University of Illinois overcame several technical challenges and successfully developed a DNA extraction method for plant tissues; this method delivers high-purity HMW DNA intended for Oxford-Nanopore long-read and ultralong-read sequencing using the Agilent Fragment Analyzer system | Developed robust and cost-effective DNA extraction method for plant tissues |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The North America next-generation sequencing (NGS) market ecosystem comprises instrument and reagent suppliers (such as Illumina, Thermo Fisher Scientific, and PacBio), bioinformatics and software providers, clinical and research laboratories, and end users, including hospitals, academic institutes, and biopharmaceutical companies. Technology vendors supply sequencing platforms, consumables, and data-analysis tools that enable high-throughput genomic testing, while laboratories integrate these solutions into clinical diagnostics, translational research, and drug development programs.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
North America NGS Market, By Offering
As of 2024, products make up the share of the North America NGS market. Strong demand for sequencing platforms, reagents, and library preparation kits in research settings supports this expectation. Products support high-throughput applications, including oncology panels, sequencing, whole-genome sequencing, and liquid biopsy. Products continue to improve chemistry, products increase throughput, and products add workflow automation. These improvements highlight the role of products in laboratories across the region.
North America NGS Products Market, By Type
By 2024, consumables had the largest share of the North America NGS products market. Consumables get used again and again because the labs need reagents, sequencing kits, and library preparation consumables for throughput oncology, rare disease, and reproductive health work. Consumables also help maintain high data quality and ensure a reliable workflow.
North America NGS Services Market, By Type
As of 2024, sequencing services make up a part of the North America NGS services market. Sequencing services are expected to remain a type of service in the years. Hospitals, academic centers, and biopharmaceutical companies want to outsource sequencing services to stay ahead. Hospitals, academic centers, and biopharmaceutical companies utilize providers for whole-genome, whole-exome, targeted panel, and RNA-sequencing work. Hospitals, academic centers, and biopharmaceutical companies do this to avoid the capital and staffing costs associated with building and running their own platforms.
North America NGS Market, By Application
As of 2024, drug discovery and development represented the largest application segment of the North America NGS market and is expected to maintain its dominance over the forecast period. Biopharmaceutical and biotechnology companies increasingly rely on NGS to identify and validate novel drug targets, discover predictive biomarkers, optimise lead candidates, and stratify patients in early and late stage clinical trials, making sequencing a core component of R&D pipelines.
REGION
The US to be the fastest-growing country in the North America NGS market during the forecast period
The US next-generation sequencing (NGS) market is expected to record one of the highest growth rates over the forecast period. Strong demand for precision oncology tests, rapid adoption of genomic profiling in rare diseases and reproductive health, and expanding use of NGS in biopharmaceutical R&D and clinical trials are key factors supporting this momentum. In the US, leading academic medical centers, national reference labs, and integrated delivery networks are rapidly scaling NGS-based panels, whole-exome sequencing, and whole-genome sequencing, supported by favorable reimbursement for selected indications. Vendors and service providers are also investing heavily in automation, cloud-based bioinformatics, and decentralized sequencing workflows, further accelerating the adoption of NGS.
North America Next-generation Sequencing Market: COMPANY EVALUATION MATRIX
In the North America NGS market matrix, Illumina (Star) leads with a dominant installed base and comprehensive NGS portfolio spanning high-throughput, benchtop, and clinical sequencers, along with reagents and bioinformatics solutions widely deployed across research, clinical, and biopharma settings. Its leadership is reinforced by strong technology innovation in sequencing-by-synthesis platforms, broad regulatory approvals, and deep integration into oncology and genetic testing workflows. BD (Emerging Leader) is gaining visibility through its growing suite of NGS library preparation and single-cell multiomics reagents, as well as automation-ready solutions that streamline sample-to-library workflows for clinical and translational research labs.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Illumina, Inc. (US)
- Thermo Fisher Scientific, Inc. (US)
- Agilent Technologies, Inc. (US)
- Danaher Corporation (US)
- Revvity (US)
- PacBio (US)
- Becton, Dickinson and Company (BD) (US)
- 10X Genomics (US)
- New England Biolabs (NEB) (US)
- Promega Corporation (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 13.9 Billion |
| Market Forecast in 2030 (Value) | USD 29.5 Billion |
| Growth Rate | CAGR of 14.6% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Countries Covered | US, Canada |
WHAT IS IN IT FOR YOU: North America Next-generation Sequencing Market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Leading academic medical center |
|
|
| NGS platform manufacturer |
|
|
RECENT DEVELOPMENTS
- October 2024: Illumina launched the MiSeq i100 sequencing systems, with high benchtop speed and simplicity, to advance NGS for labs.
- July 2024: Illumina acquired Fluent BioSciences, a developer of an emerging and highly differentiated single-cell technology. This will help advance multi-omics growth strategies.
- June 2024: Thermo Fisher Scientific expanded its central operations laboratory in Kentucky, US, to accelerate the pharmaceutical and biotech operations.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study on the next-generation sequencing market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the next-generation sequencing market using several research strategies, the size of the final market was obtained by triangulating data from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources. These include the Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the World Health Organization (WHO), the American Cancer Society (ACS), the National Center for Biotechnology Information (NCBI), the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), International Agency for Research on Cancer (IARC), National Institute for Infectious Diseases (IRCCS), Association for Clinical Genomic Science (ACGS), American Society of Human Genetics (ASHG), European Society of Human Genetics (ESHG), Asia Pacific Society of Human Genetics (APSHG), Nature Reviews Genetics, Nature Methods, Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Genome Research, National Cancer Institute (NCI), European Medicines Agency (EMA), Population Health Research Institute (PHRI), PubMed, World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global next-generation sequencing market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global next-generation sequencing market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing NGS; experts from the demand side, such as personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the next-generation sequencing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
NGS refers to non-Sanger-based, high-throughput DNA sequencing technologies. DNA strands can be sequenced simultaneously, yielding substantially more throughput and minimizing the need for fragment-cloning methods often used in the Sanger sequencing of genomes. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.
Stakeholders
- NGS instrument manufacturers, vendors, and distributors
- NGS service providers
- NGS bioinformatics/data analysis companies
- Research laboratories and academic institutes
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Healthcare institutions (hospitals and diagnostic clinics)
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the next-generation sequencing market based on offerings, product type, platform technology, product workflow, product end user, service type, service workflow, service end user, application, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall next-generation sequencing market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global next-generation sequencing market and comprehensively analyze their platforms, reagents, kits, consumables, and services portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the next-generation sequencing market
- To benchmark players within the next-generation sequencing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the North America Next-generation Sequencing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in North America Next-generation Sequencing Market